Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, ...
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
Nvidia's positions in these companies were relatively small at the end of the third quarter of 2025, but the chipmaker has spent recent years building a portfolio of AI‑related investments across ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
AI agents are powerful, but without a strong control plane and hard guardrails, they’re just one bad decision away from chaos. The first time I watched an autonomous AI agent execute a multi-step ...
NPR's Scott Simon speaks to writer Matt Klein about how to win back our attention in an age of infinite information. UNIDENTIFIED PERSON: (Laughter). SIMON: Oh, I - yeah. Oh, I - my daughter just sent ...
Correspondence to Dr ST Fonseca, Graduate Program in Rehabilitation Science, Physical Therapy Department, Universidade Federal de Minas Gerais, Minas Gerais, Avenida Presidênte Antônio Carlos, ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results